Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 9/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | PRCP | P42785 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9330574 | 0.97 | CHRM2 (0.55) | CHRM2CHRM1ALDH1A1LMNACYP1A2 | |
| SCHEMBL7629979 | 0.79 | SLC6A2 (0.38) | CYP2D6SLC6A2SLC6A3 | |
| SCHEMBL18261095 | 0.77 | PRCP (0.48) | CHRM2CHRM1ALDH1A1LMNACYP1A2 | |
| SCHEMBL6660824 | 0.76 | SLC6A2 (0.43) | LMNACYP2D6KDM4EHTTSLC6A2 | |
| SCHEMBL11217551 | 0.76 | CHRM2 (0.37) | CHRM2CHRM1SIGMAR1TMEM97 | |
| SCHEMBL4661013 | 0.75 | SLC6A2 (0.44) | LMNACYP2D6SIGMAR1HTTSLC6A2 | |
| Hydrochloric Acid SCHEMBL4021178 | 0.74 | SLC6A2 (0.43) | LMNACYP2D6SIGMAR1KDM4EHTT | |
| SCHEMBL28838197 | 0.73 | AKR1C1 (0.45) | CYP2D6KDM4ESLC6A2OPRM1SLC6A3 | |
| SCHEMBL67880 | 0.72 | PRCP (0.54) | CHRM2CHRM1ALDH1A1LMNACYP1A2 | |
| SCHEMBL8112597 | 0.72 | SLC6A2 (0.43) | LMNACYP2D6SIGMAR1HTTSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3104847-B1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TAMOGATOTT KUTATOCSOPORTOK IRODAJA (HU) | 2020-11-11 | — | — | EP | claimed |
| CN-106456578-B | Use of SIGMA-1 receptor agonist compounds | 匈牙利科学院大学及其他机构附属研究所 | 2020-02-18 | — | — | CN | claimed |
| EP-3104847-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | Mta Támogatott Kutatócsoportok Irodája (HU) | 2016-12-21 | — | — | EP | claimed |
| US-20160346290-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2016-12-01 | — | — | US | claimed |
| WO-2015118365-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | MTA TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) | 2015-08-13 | — | — | WO | claimed |
| CN-106456578-B | Use of SIGMA-1 receptor agonist compounds | 匈牙利科学院大学及其他机构附属研究所 | 2020-02-18 | — | — | CN | disclosed |
| US-6566396-B2 | Carbetapentane tannate and chlorpheniramine tannate which are effective when administered orally for the symptomatic relief of coryza associated with the common cold, sinusitis, allergic rhinitis, and unproductive cough | MEDPOINTE HEALTHCARE INC. | 2003-05-20 | — | — | US | disclosed |
| US-6455727-B1 | Process for preparing carbetapentane tannate | JAME FINE CHEMICALS, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20020099021-A1 | Antitussive/antihistaminic compositions | CARTER-WALLACE, INC. | 2002-07-25 | — | — | US | disclosed |
| US-20010011104-A1 | ANTIHISTAMINE COMPOSITIONS | MEDPOINTE HEALTHCARE INC. | 2001-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346290-A1 | NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS | SIGMAR1, TMEM97, OPRL1 | CHRM2 132/4885CHRM1 94/4885ALDH1A1 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.